Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 15

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
 NHS Foundation Trust (“GOSH”) entered into a license agreement for the exclusive commercial use
to clinical trial data associated with a GOSH study investigating the potential of CORDStrom to treat RDEB in pediatric patients (the
“MissionEB study”). The Company owns the intellectual property covering CORDStrom, the investigational medicinal product used
in the Mission EB study. In addition, the Company owns intellectual property and maintains trade secret protections covering the manufacturing
of CORDStrom. With this license to the clinical trial data, the Company intends to prepare applications seeking marketing authorization
of CORDStrom for treatment of pediatric RDEB in each of the FDA, EMA, and MHRA. Terms of the license agreement include an upfront payment
of £250,000 (approximately $0.3 million at June 30, 2025) and a single milestone payment of up to £6,000,000 (approximately
$8.2 million as of June 30, 2025) due on the first to occur marketing authorization to be granted by the FDA, EMA or MHRA, which had not
occurred as of June 30, 2025. At June 30, 2025 and December 31, 2024, the Company recorded $0.3 million and $0, respectively, payable
to GOSH within accounts payable and accrued liabilities in the consolidated balance sheets.

Pursuant to the GOSH license agreement, the Company
has an obligation to provide CORDStrom to the MissionEB study at no cost. While Part 1 of the study is completed, Part 2 of the MissionEB
study is currently uninitiated due to a lack of funding by the National Health Services England (“NHSE”). It is unknown whether
funding for the study will be allocated by NHSE or its successor agency in the United Kingdom. The Company has not recorded an estimated
obligation for the supply of the MissionEB trial with CORDStrom as it is unknown if the MissionEB trial will resume.

INKmune License Agreement

On October 29, 2015, the Company entered into
an exclusive license agreement (the “INKmune License Agreement”) with Immune Ventures, LLC (“Immune Ventures”).
Pursuant to the INKmune License Agreement, the Company was granted exclusive worldwide rights to the patents, including rights to incorporate
any improvements or additions to the patents that may be developed in the future.